QUOTE AND NEWS
Benzinga  Mar 2  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) posted better-than expected fourth quarter results on Monday, but offered a revenue forecast shy of analysts' consensus. The San Diego-based drug development company changed hands recently in the...
Forbes  Feb 27  Comment 
Halozyme Therapeutics is expected to book a narrower loss than a year ago when it reports fourth-quarter earnings on Monday, March 2, 2015. Analysts are expecting a loss of nine cents per share, up from a loss of 19 cents per share a year ago.The...
Benzinga  Jan 8  Comment 
Neurocrine Biosciences Inc. (NASDAQ: NBIX) surged 21.07% to $26.49. The volume of Neurocrine Biosciences shares traded 1407% higher than normal. AbbVie Inc. (NYSE: ABBV), in cooperation with Neurocrine Biosciences, announced positive top-line...
Benzinga  Jan 8  Comment 
In a report published Thursday, MLV & Co analyst Arlinda Lee reiterated a Buy rating on Halozyme Therapeutics (NASDAQ: HALO), and raised the price target from $12.00 to $15.00. In the report, MLV & Co noted, “During its analyst day, HALO...
Benzinga  Jan 7  Comment 
Stocks have been getting hit pretty hard over the last week. The new year has started off somewhat like 2014 did -- down. Some individual industries are holding up a little better than others, such as gold miners, REITs and...
Benzinga  Jan 6  Comment 
Some recent news has Halozyme Therapeutics, Inc. (NASDAQ: HALO) trending back in the right direction after a rocky 2014. On December 17, Janssen entered into a partnership agreement to commercialize subcutaneous products using ENHAZE...
Benzinga  Dec 24  Comment 
Analysts at MLV & Co initiated coverage on Halozyme Therapeutics, Inc. (NASDAQ: HALO) with a Buy rating. The target price for Halozyme Therapeutics is set to $12. Halozyme Therapeutics shares have dropped 42.48% over the past 52 weeks,...
FierceBiotech  Dec 17  Comment 
Johnson & Johnson has signed a deal to use Halozyme Therapeutics' drug delivery platform in its own R&D efforts, agreeing to pay as much as $581 million for the privilege.
GenEng News  Dec 17  Comment 
Janssen has obtained a worldwide license to Halozyme’s Enhanze technology with the goal of developing and commercializing products combining Janssen compounds with Enhanze technology. Enhanze is based on a proprietary recombinant human...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki